Alnylam Pharmaceuticals Inc
ALNY: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $654.00 | Rzknb | Vlgjlpbb |
Alnylam: Shares Soar on Positive Phase 3 Results for Vutrisiran; Raising Fair Value Estimate
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
Narrow-moat Alnylam announced positive top-line results from the HELIOS-B Phase 3 study of its investigational RNAi therapeutic, vutrisiran, to treat patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). Investors reacted quite favorably to the good news and have sent the stock up over 40%. We have raised our fair value estimate to $223 per share from $199 due to an increased probability of approval of 85% for this pipeline candidate based on the positive clinical trial results.